We propose the combination of JPX and its downstream gene urokinase-type plasminogen activator (PLAU) inhibitors as a novel therapeutic strategy to target HNSCC and provide new insights into precision oncology (Supplementary Fig. S15). The gene discussed is PLAU; the disease is head and neck squamous cell carcinoma.